

shalviri\_g@yahoo.com

// : // :

Bayesian Confidence Propagation Neural Network (BCPNN) :

Proportional Reporting Ratio (PRR) Reporting Odds Ratio(ROR)

$\geq \geq , \geq$

BCPNN

PRR

ROR

BCPNN

.()

[Uppsala Monitoring Center

(UMC) ]

.( )

WHO

Bayesian

Bayesian Confidence ) BCPNN .( )

(Propagation Neural Network

.( )

Medicines )

.( )

(Control Agency or MCA

(PRRs)

Proportional Reporting Ratios

Evans .

.( )

ADR

.( )

PRR

( % ) 487

( % )

Proportional (PRRs) ,

(% )

Bayesian data mining Reporting Ratios

(% )

(% )

Prescription ) PEM

(Event Monitoring

FDA

Empirical ) EBS Data mining  
( ) ( Bayesian Screening

Proportional

Reporting Odds Ratios ,Reporting Ratios

Neural Network Bayesian

( )

Slone Epidemiology Unit or ) Slone

( SEU

(.)

Excel

odds ratios

)

( (crude)

WHO Adverse Drug Reaction )

( ) (Terminology

---

Reporting Odds (ROR) ( Preferred Term)

Ratio

ROR ( )

%

ROR

ROR

%

Access

Query

:

b

a

d

c

( )

:

Bayesian Confidence

Propagation Neural Network ( BCPNN)

Proportional Reporting Ratio (PRR)

Reporting Odds Ratio (ROR)

Bayesian Confidence Propagation Neural Network (BCPNN)

Information ) IC ( )

(Component

( )

%

IC

PRR

IC-2SD

chi – squared

IC-2SD

IC-2SD &gt; 0

PRR

PRR ≥

(

Chi-squared

PRR % (

.( )

≥ ≥ , ≥ % PRR

cut-off

PRR ≥ 2,  $\chi^2 \geq 4$  :

≥

≥ ≥

ROR

%

IC

IC-2SD

) PRR

(% / )

(

( / %)

% /

) ROR

(% / )

(

cut-

(% / )

off

(% , )

) IC

(% , )

(

SNIP

.( )

(Strength)

(% / )

(NEW )

)

(Clinical Importance) (

IVIG

( Potentially preventable)

(SNIP)

%

%

.( )

% / % /

BCPNN , ROR , PRR

% /

IC-2SD

PRR  
( proportional mortality ratios )  
PRR  
BCPNN PRRs  
FDA EBS WHO  
(  
UK Medicines Control Agency MCA) PRR  
( % )  
chi- PRR  
association squared  
UK yellow card system  
/ / PRR

PRRs  
MCA  
Important New Strong) SNIP  
( Preventable  
EBS BCPNN PRRS

IVIG

BCPNN

WHO

BCPNN

WHO

BCPNN

( )

PRRs

BCPNN EBS

NSAIDs

( RORs PRRs )

BCPNN IC

( )



---

---

---

% ,	% ,	PRR $\geq 2$ , $\chi^2 \geq 4$	$\geq$
% ,	% ,	ROR, CI>1	
% ,	% ,	PRR, CI>1	
% ,	% ,	IC, IC-2SD>0	
% ,	% ,	PRR $\geq 2$ , $\chi^2 \geq 4$	$\geq$
% ,	% ,	ROR, CI>1	
% ,	% ,	PRR, CI>1	
% ,	% ,	IC, IC-2SD>0	
% ,	% ,	PRR $\geq 2$ , $\chi^2 \geq 4$	$\geq$
% ,	% ,	ROR, CI>1	
% ,	% ,	PRR, CI>1	
% ,	% ,	IC, IC-2SD>0	

---

## References

- 1- World Health organization. The importance of pharmacovigilance, safety monitoring of medicinal products. WHO: Geneva, 2002.
- 2- Mann R.D, Andrews E.B, Pharmacovigilance. John Wiley & Sons Ltd. 2002.
- 3- Boxel J.V, Santoso B., Edwards I.R. Drug benefits and Risks, International textbook of clinical pharmacology. John Wiley & Sons Ltd. 2001.
- 4- Meyboom, R.H.B. Detecting Adverse Drug reactions, Pharmacovigilance in the Netherlands. The Netherlands pharmacovigilance Foundation LAREB.1998.
- 5- Meyboom, R.H.B., Egberts, A.C.G. Edwards, I.R. Principles of Signal Detection in Pharmacovigilance. Drug Safety 1997; 16 (6): 355-365.
- 6- Hauben, M. Zhout, X. Quantitative methods in pharmacovigilance, focus on signal detection. Drug Safety 2003; 26(3): 159-186.
- 7- Bate, A. Lindquist, M. Edwards, I.R. Orre, R. A data mining approach for signal detection and analysis. Drug Safety 2002; 25(6): 393-397.
- 8- Evans, S. J. W. Waller, P. C. Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoeconomics and drug safety 2001; 10: 483-486.
- 9- Szarfman, A. Machado, S.G. O'Neill, R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Safety 2002; 25(6): 381-392.
- 10- Gould, A.L. Practical pharmacovigilance analysis strategies. Pharmacoeconomics and drug safety 2003; 12: 559-574.
- 11- WHO adverse reaction terminology. the Uppsala Monitoring Center, 2003.
- 12- WHO Collaborating Center for International Drug Monitoring, Viewpoint, watching for safer medicines. Part 2. the Uppsala Monitoring Center, 2004; 56.
- 13- Waller, P.C. Lee, E.H. Responding to drug safety issues. Pharmacoeconomics and drug safety. 1999; 8: 535-552.
- 14- Puijtenbroek, E.P. Grootheest, K. Diemont, W.L. Leufkens, H.G. M. Egberts, A.C.G. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol, 2001, 52, 579-586.
- 15- Stahl, M. Lindquist, M. Edwards I. R. Brown, E.G. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoeconomics and drug safety 2004; 13: 355-363.
- 16- Puijtenbroek, E.P. Bate, A. Leufkens, HGM. Lindquist, M. Orre, R. Egberts, ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoeconomics and drug safety 2002; 11: 3-10.

